IonQ stock opened at $37.87 on Wednesday, sitting well below the analyst average price target of $69.92. The stock has a 12-month range of $25.89 to $84.64, and carries a market cap of $14.43 billion.
The company’s investor day on September 8 is shaping up to be one of the more closely watched events in the quantum computing space right now. Analysts expect the SkyWater Technology acquisition to dominate the agenda.
StoneX analyst Gary Mobley says IonQ’s dealmaking is the story here. The $1.8 billion SkyWater deal, which closed in late July, is the company’s largest acquisition ever and gives IonQ control of its own chip foundry.
That means IonQ can now offer semiconductor fabrication, chip design, and advanced packaging to other companies. It is a big shift for a firm that started as a pure-play quantum computing business.
Mobley believes the SkyWater deal could pull IonQ’s road map for a 200,000 qubit system forward by roughly a year. That timeline lines up with a recent executive order calling for a fault-tolerant quantum computer at a national lab by 2028.
The financial picture is not straightforward. Because IonQ was already a major SkyWater customer, analysts cannot simply add SkyWater’s revenue on top. Mobley says investors need to reduce SkyWater’s revenue contribution by about 20% to account for canceled internal transactions.
IonQ was on track to pay SkyWater $120 million in 2026, with $80 million of that in the second half of the year. Current consensus estimates do not yet factor in the full SkyWater impact.
Mobley also expects the deal to compress combined profit margins and absorb around $93 million in operating expenses this year. Full guidance on the acquisition’s financial impact is expected at the September 8 event.
IonQ’s Q2 results gave investors something to work with in the meantime. Revenue hit $80.05 million, up 286.7% year over year, and beat expectations of $66.47 million. The adjusted loss per share was $0.33, better than the $0.56 analysts had penciled in.
A new development this week gave IonQ more to talk about heading into investor day. The company and QC Ware demonstrated a hybrid quantum-classical chemistry workflow using IonQ’s Forte system through Amazon Braket.
The test produced enzyme interaction-energy results within 4% of a benchmark, hitting the chemical-accuracy threshold cited for pharmaceutical research. It opens a potential path into drug discovery, an area beyond IonQ’s traditional focus.
CEO Niccolo de Masi has not been shy about his ambitions. “Our ambition is always to be the Nvidia of quantum,” he told Barron’s after the last earnings call.
Nine analysts currently rate the stock a Buy, four say Hold, and one has a Sell rating. IonQ’s public warrants expire on September 30, and if exercised, they could increase the share count and add near-term pressure on the stock.
The post IonQ Stock Has a Big Week Ahead. Here Is What Analysts Expect appeared first on CoinCentral.
